Nothing Special   »   [go: up one dir, main page]

ECSP20070185A - Análogos novedosos de glp-1 - Google Patents

Análogos novedosos de glp-1

Info

Publication number
ECSP20070185A
ECSP20070185A ECSENADI202070185A ECDI202070185A ECSP20070185A EC SP20070185 A ECSP20070185 A EC SP20070185A EC SENADI202070185 A ECSENADI202070185 A EC SENADI202070185A EC DI202070185 A ECDI202070185 A EC DI202070185A EC SP20070185 A ECSP20070185 A EC SP20070185A
Authority
EC
Ecuador
Prior art keywords
analogs
glp
action
new
present disclosure
Prior art date
Application number
ECSENADI202070185A
Other languages
English (en)
Inventor
Ravishankara Madavati Nagaraja
Kunal Pandya
Abhishek Tiwari
Rishit Mansukhlal Zalawadia
Nishith Chaturvedi
Vinod Sampatrao Burade
Dhiren Rameshchandra Joshi
Vipulkumar Shankarbhai Pa-Tel
Brijeshkumar Patel
Pradeep Dinesh Shahi
Krunal Harishbhai Soni
Rajamannar Thennati
Muthukumaran Natarajan
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of ECSP20070185A publication Critical patent/ECSP20070185A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

La presente descripción se refiere a análogos novedosos del péptido similar al glucagón-1 (GLP-1) (7-37) que tienen una secuencia de aminoácidos con Leu o Ile en el C-terminal. Los nuevos análogos son potentes agonistas de GLP-1 con efecto adverso reducido y duración de la acción mejorada. La presente descripción se refiere además a derivados acilados de los nuevos análogos que tienen una potencia y duración de la acción mejoradas adicionalmente y son adecuados para la administración oral. Los análogos de la presente descripción pueden ser útiles en el tratamiento de la diabetes y la obesidad.
ECSENADI202070185A 2018-04-05 2020-11-05 Análogos novedosos de glp-1 ECSP20070185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040474 2018-10-26
IN201821040468 2018-10-26

Publications (1)

Publication Number Publication Date
ECSP20070185A true ECSP20070185A (es) 2021-01-29

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202070185A ECSP20070185A (es) 2018-04-05 2020-11-05 Análogos novedosos de glp-1

Country Status (31)

Country Link
US (7) US11447535B2 (es)
EP (3) EP4364751A3 (es)
JP (2) JP7250814B2 (es)
KR (1) KR20200141469A (es)
CN (2) CN117964735A (es)
AU (2) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
DK (2) DK4122954T3 (es)
EC (1) ECSP20070185A (es)
ES (2) ES2925678T3 (es)
FI (1) FI4122954T3 (es)
HR (2) HRP20240749T1 (es)
HU (2) HUE060135T2 (es)
IL (1) IL277483A (es)
JO (1) JOP20200251A1 (es)
LT (2) LT3774862T (es)
MX (2) MX2020010505A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (2) PL4122954T3 (es)
PT (2) PT4122954T (es)
RS (2) RS63523B1 (es)
SG (1) SG11202009467YA (es)
SI (2) SI4122954T1 (es)
SM (2) SMT202200352T1 (es)
UA (1) UA128210C2 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010505A (es) * 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
WO2022079639A1 (en) * 2020-10-17 2022-04-21 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
JP7604666B2 (ja) 2021-01-20 2024-12-23 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2024261580A1 (en) 2023-06-20 2024-12-26 Sun Pharmaceutical Industries Limited Glp-1 analog for use in the treatment of metabolic disorders
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
ATE466028T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2322545A1 (en) 1998-12-07 2011-05-18 Ipsen Pharma Analogues of GLP-1
ATE346093T1 (de) 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
EA005584B1 (ru) 2000-12-07 2005-04-28 Эли Лилли Энд Компани Слитые белки glp-1
BR0306706A (pt) 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
AU2003272970B2 (en) 2002-10-11 2009-05-28 Sanwa Kagaku Kenkyusho Co. Ltd. GLP-1 derivatives and transmicosal absorption preparations thereof
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性glp−1化合物
WO2006097538A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
AU2006287562B2 (en) 2005-09-08 2012-05-10 Trustees Of Tufts College Stabilized GLP-1 analogs
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US8648041B2 (en) 2009-12-16 2014-02-11 Novo Nordisk A/S Double-acylated GLP-1 derivatives
ES2548259T3 (es) 2010-04-27 2015-10-15 Betta Pharmaceuticals Co., Ltd. Análogo del péptido similar al glucagón-1 y uso del mismo
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
JP6366575B2 (ja) 2012-05-08 2018-08-01 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
JP2015525226A (ja) 2012-06-14 2015-09-03 サノフイ エキセンディン−4ペプチドアナログ
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
EP2934567B9 (en) 2012-12-21 2018-08-22 Sanofi Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists
WO2014202727A1 (en) 2013-06-20 2014-12-24 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
MX2015016875A (es) 2013-07-04 2016-04-07 Novo Nordisk As Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
UA122767C2 (uk) * 2013-10-17 2021-01-06 Зіленд Фарма А/С Ацильований аналог глюкагону
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086686A2 (en) 2013-12-13 2015-06-18 Medimmune Limited Protease resistant peptides
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重glp-1/升糖素受體促效劑之艾塞那肽-4胜肽類似物
ES2739289T3 (es) 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
JP6691125B2 (ja) 2014-12-17 2020-04-28 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
US10111932B2 (en) 2015-08-26 2018-10-30 Syracuse University Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor
EP3423481B1 (en) 2016-03-03 2020-10-07 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CN109195984A (zh) 2016-06-09 2019-01-11 免疫医疗有限公司 蛋白酶抗性的单-脂化肽
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
WO2018178796A1 (en) 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
US10883132B2 (en) 2018-03-09 2021-01-05 Enzypep B.V. Chemo-enzymatic synthesis of Semaglutide, Liraglutide and GLP-1
MX2020010505A (es) * 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.

Also Published As

Publication number Publication date
CN112236444A (zh) 2021-01-15
JOP20200251A1 (ar) 2020-10-04
EP4364751A3 (en) 2024-06-26
SG11202009467YA (en) 2020-10-29
EP4122954A1 (en) 2023-01-25
RS63523B1 (sr) 2022-09-30
HUE060135T2 (hu) 2023-02-28
SI3774862T1 (sl) 2022-10-28
HRP20240749T1 (hr) 2024-09-13
IL277483A (en) 2020-11-30
EP3774862A1 (en) 2021-02-17
AU2023203430A1 (en) 2023-06-29
PT4122954T (pt) 2024-06-05
US11242373B2 (en) 2022-02-08
ZA202306729B (en) 2024-03-27
PT3774862T (pt) 2022-09-05
SMT202400241T1 (it) 2024-07-09
CN117964735A (zh) 2024-05-03
LT4122954T (lt) 2024-06-25
MX2020010505A (es) 2021-01-15
AU2019247936C1 (en) 2023-06-15
CO2020012425A2 (es) 2020-12-21
US20190309040A1 (en) 2019-10-10
JP2023078367A (ja) 2023-06-06
JP2021520346A (ja) 2021-08-19
HUE067499T2 (hu) 2024-10-28
ES2980707T3 (es) 2024-10-02
DK4122954T3 (da) 2024-06-10
US11873328B2 (en) 2024-01-16
LT3774862T (lt) 2022-09-12
EP4364751A2 (en) 2024-05-08
SMT202200352T1 (it) 2022-09-14
PL3774862T3 (pl) 2022-10-03
US11866477B2 (en) 2024-01-09
US20220402992A1 (en) 2022-12-22
AU2019247936B2 (en) 2023-03-02
US20200362007A1 (en) 2020-11-19
US11485766B2 (en) 2022-11-01
AU2019247936A1 (en) 2020-10-15
US20240199718A1 (en) 2024-06-20
DK3774862T3 (da) 2022-09-05
RS65639B1 (sr) 2024-07-31
ES2925678T3 (es) 2022-10-19
UA128210C2 (uk) 2024-05-08
PE20211417A1 (es) 2021-08-02
US20240376175A1 (en) 2024-11-14
CL2020002574A1 (es) 2021-06-04
HRP20221054T1 (hr) 2022-11-11
EP3774862B1 (en) 2022-06-08
CA3095988A1 (en) 2019-10-10
US11447535B2 (en) 2022-09-20
SI4122954T1 (sl) 2024-07-31
PL4122954T3 (pl) 2024-08-12
PH12020551591A1 (en) 2021-08-16
FI4122954T3 (fi) 2024-06-18
MX2024007688A (es) 2024-07-09
EP4122954B1 (en) 2024-04-03
WO2019193576A1 (en) 2019-10-10
US20210206823A1 (en) 2021-07-08
KR20200141469A (ko) 2020-12-18
JP7250814B2 (ja) 2023-04-03
US20220402991A1 (en) 2022-12-22
BR112020020419A2 (pt) 2021-01-19

Similar Documents

Publication Publication Date Title
ECSP20070185A (es) Análogos novedosos de glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
CL2021000158A1 (es) Compuestos coagonistas de gip/glp1
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
AR109274A2 (es) Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
PE20151770A1 (es) Compuesto peptidico
RU2011129784A (ru) Основанные на амидах пролекарства пептидов глюкагонового надсемейства
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
AR081200A1 (es) Formulaciones de insulina de accion prolongada
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
PE20200606A1 (es) Composiciones solidas para administracion oral
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
PE20171380A1 (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
PE20221518A1 (es) Analogos de incretina y sus usos
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
AR128464A1 (es) Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada
AR094358A1 (es) Derivados de péptidos insulinotrópicos cuya carga n-terminal está modificada
EA202092017A1 (ru) Новые аналоги glp-1
MX2021012177A (es) Usos terapeuticos de dulaglutida.
AR119324A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1